These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 26052395)

  • 21. Chronic hepatitis B--who should be treated?
    Coffin CS; Lee SS
    MedGenMed; 2006 Mar; 8(1):75. PubMed ID: 16915205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Sayan M; Buğdacı MS
    Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients.
    De Nicolò A; Simiele M; Pensi D; Boglione L; Allegra S; Di Perri G; D'Avolio A
    J Pharm Biomed Anal; 2015 Oct; 114():127-32. PubMed ID: 26037161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
    Han C; Lai PP; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure.
    Yoo J; Hann HW; Coben R; Conn M; DiMarino AJ
    Diseases; 2018 Apr; 6(2):. PubMed ID: 29677098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG; Mohammed R; Yuen MF; Kao JH
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Interdisciplinary aspects of and new drugs for chronic hepatitis B].
    Horváth G
    Orv Hetil; 2013 Jul; 154(29):1142-50. PubMed ID: 23853347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M; Della Corte C; Colombo M
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Hepatol Int; 2008 Jun; 2(2):163-78. PubMed ID: 19669301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral hepatitis B and hepatocellular carcinoma.
    Michielsen P; Ho E
    Acta Gastroenterol Belg; 2011 Mar; 74(1):4-8. PubMed ID: 21563647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    European Association for the Study of the Liver
    J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy.
    Varbobitis I; Papatheodoridis GV
    Clin Mol Hepatol; 2016 Sep; 22(3):319-326. PubMed ID: 27729632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study.
    Inoue J; Akahane T; Nakayama H; Kimura O; Kobayashi T; Kisara N; Sato T; Morosawa T; Izuma M; Kakazu E; Ninomiya M; Iwata T; Takai S; Nakamura T; Sano A; Niitsuma H; Masamune A;
    Hepatol Res; 2019 Nov; 49(11):1263-1274. PubMed ID: 31254482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.
    Papatheodoridis GV; Chan HL; Hansen BE; Janssen HL; Lampertico P
    J Hepatol; 2015 Apr; 62(4):956-67. PubMed ID: 25595883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
    Wei L; Kao JH
    Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
    Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
    Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.